Zhao Yan New Medicine (06127) achieved a net profit attributable to the parent of 80.7061 million yuan in the first three quarters, turning losses into profits year-on-year.

The Zhongtong Finance and Economics APP reports that Zhaoyan Pharmaceuticals (06127) has announced that in the first three quarters of 2025, the group achieved operating income of 985 million yuan, a decrease of 26.23% year-on-year; net profit attributable to shareholders was 80.7061 million yuan, compared to a loss of 70.3071 million yuan in the same period last year; basic earnings per share were 0.11 yuan.